Project Grant R43HL170918
Award Date
9/1/23
Completion Date
8/31/24
Dollars Obligated
$343K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,283,558 to the Massachusetts Institute of Technology (MIT) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The purpose of this 4-year grant, with a start date of August 1, 2024, is to develop and demonstrate the concept of Multi-Electroplasmonic Nanoantenna Arrays (MENAS) - a breakthrough wireless technology for high-resolution, intracellular electrophysiological recording of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research, supports the development of a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award, with a period of performance from September 2024 to July 2026, aims to construct the bioelectronic platform, optimize its delivery and...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $294,993 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Sensoriis Inc. in Edmonds, WA. The goal of this 1-year project is to develop a Zebrafish Automatic Cardiovascular Assessment System (ZACAS) to provide a fast, economic, and easy solution for researchers to assess cardiac functions in developing zebrafish embryos. Specifically, the project...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Clemson University a $580,863 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and optimize silicon nanowire-engineered human cardiac organoids for heart repair. The key products and services being delivered include: Determining the optimal surface roughness of electrically conductive silicon nanowires to improve their interactions with human pluripotent stem cell-derived cardiomyocytes in...
This $590,283 Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop feedback-controlled closed-loop manufacturing processes to improve the robustness and reproducibility of differentiating human pluripotent stem cells into cardiomyocytes. The overarching goal is to address the challenges of variability and cost in manufacturing cellular therapies, with a focus on enabling more...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $304,119 to Endomimetics LLC to develop innovative in vitro models and assays for screening atherosclerosis treatments. The goal is to create a highly automated, precise approach for fabricating 3D vascular sheets and atherosclerosis models to enable efficient, high-throughput drug testing in a human-relevant environment. Specifically,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, particularly for patients with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of computational tools to link single-cell RNA sequencing (scRNAseq) data to physiological predictions for different cardiomyocyte subtypes. The total funding amount is $252,854, with a project period from September 1, 2024, to August 31, 2026. The key objectives of this award are to: 1) use scRNAseq to...
This federal Project Grant award of $251,156 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a betavoltaic power source for leadless cardiac pacemakers (LCPs). The project will leverage advanced polyimide packaging and manufacturing methods to create a miniaturized, long-lasting power source for LCPs, reducing their size and extending device lifespan beyond the current 7-10 years provided by lithium-based...